Susan Melin to Adenocarcinoma
This is a "connection" page, showing publications Susan Melin has written about Adenocarcinoma.
Connection Strength
0.122
-
Mishra G, Butler J, Ho C, Melin S, Case LD, Ennever PR, Magrinat GC, Bearden JD, Minotto DC, Howerton R, Levine E, Blackstock AW. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol. 2005 Aug; 28(4):345-50.
Score: 0.052
-
Blackstock AW, Melin SA, Butler JM, Patton S, Pineau B, Albertson D, Howerton R, Levine E. Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer. Oncology (Williston Park). 2002 May; 16(5 Suppl 5):25-8.
Score: 0.042
-
Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, Melin SA, Lovato J, Oaks T, Blackstock AW. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006 Apr; 243(4):472-8.
Score: 0.014
-
Blackstock AW, Aklilu M, Lovato J, Farmer MR, Mishra G, Melin SA, Oaks T, Geisinger K, Levine EA. Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer. Int J Gastrointest Cancer. 2006; 37(1):7-14.
Score: 0.013